INTRODUCTION AND HYPOTHESIS: The aim of this manuscript was to provide a systematic literature review of clinical trial evidence for a range of electrical stimulation therapies in the treatment of lower urinary tract symptoms (LUTS). METHODS: The databases MEDLINE, BIOSIS Previews, Inside Conferences, and EMBASE were searched. Original clinical studies with greater than 15 subjects were included. RESULTS: Seventy-three studies were included, representing implanted sacral nerve stimulation (SNS), percutaneous posterior tibial nerve stimulation (PTNS), and transcutaneous electrical stimulation (TENS) therapy modalities. CONCLUSIONS: Median mean reductions in incontinence episodes and voiding frequency were similar for implanted SNS and PTNS. However, long-term follow-up data to validate the sustained benefit of PTNS are lacking. Despite a substantial body of research devoted to SNS validation, it is not possible to definitively define the appropriate role of this therapy owing largely to study design flaws that inhibited rigorous intention to treat analyses for the majority of these studies.
INTRODUCTION AND HYPOTHESIS: The aim of this manuscript was to provide a systematic literature review of clinical trial evidence for a range of electrical stimulation therapies in the treatment of lower urinary tract symptoms (LUTS). METHODS: The databases MEDLINE, BIOSIS Previews, Inside Conferences, and EMBASE were searched. Original clinical studies with greater than 15 subjects were included. RESULTS: Seventy-three studies were included, representing implanted sacral nerve stimulation (SNS), percutaneous posterior tibial nerve stimulation (PTNS), and transcutaneous electrical stimulation (TENS) therapy modalities. CONCLUSIONS: Median mean reductions in incontinence episodes and voiding frequency were similar for implanted SNS and PTNS. However, long-term follow-up data to validate the sustained benefit of PTNS are lacking. Despite a substantial body of research devoted to SNS validation, it is not possible to definitively define the appropriate role of this therapy owing largely to study design flaws that inhibited rigorous intention to treat analyses for the majority of these studies.
Authors: R A Schmidt; U Jonas; K A Oleson; R A Janknegt; M M Hassouna; S W Siegel; P E van Kerrebroeck Journal: J Urol Date: 1999-08 Impact factor: 7.450
Authors: A C van Voskuilen; D J A J Oerlemans; E H J Weil; R A de Bie; Ph E V A van Kerrebroeck Journal: Eur Urol Date: 2006-01-04 Impact factor: 20.096
Authors: W A Scheepens; M M G J Jongen; F H M Nieman; R A de Bie; E H J Weil; P E V van Kerrebroeck Journal: Urology Date: 2002-10 Impact factor: 2.649
Authors: Vera Vandoninck; Michael R van Balken; Enrico Finazzi Agrò; Filomena Petta; Francesco Micali; John P F A Heesakkers; Frans M J Debruyne; Lambertus A L M Kiemeney; Bart L H Bemelmans Journal: Neurourol Urodyn Date: 2003 Impact factor: 2.696
Authors: Anco C Van Voskuilen; Dennis J A J Oerlemans; Ernest H J Weil; Ubi van den Hombergh; Philip E V A van Kerrebroeck Journal: BJU Int Date: 2006-09-06 Impact factor: 5.588
Authors: R A Janknegt; M M Hassouna; S W Siegel; R A Schmidt; J B Gajewski; D A Rivas; M M Elhilali; D C Milam; P E van Kerrebroeck; H E Dijkema; A A Lycklama à Nÿeholt; M Fall; U Jonas; F Catanzaro; C J Fowler; K A Oleson Journal: Eur Urol Date: 2001-01 Impact factor: 20.096